WELLESLEY HILLS, Mass., Feb. 21 /PRNewswire-FirstCall/ -- MacroChem's President and CEO, Robert DeLuccia, will present at the upcoming Equities Magazine Emerging Growth Stock Day Conference at the Yale Club in New York City on February 23, 2007. Mr. DeLuccia is scheduled to present at 10:40 AM EST.
The Equities Corporate Conference is a half day event featuring special presentations from 12 emerging public company CEOs. The conference provides an opportunity for promising emerging growth companies to connect with the investment community. Interested parties can access a live audio webcast of the Company's presentation, through a link at www.equitiesmagazine.com. The presentation will be available for 90 days.
About MacroChem
MacroChem Corporation is a specialty pharmaceutical company with two clinical development stage products containing our patented enhancer, SEPA(R): EcoNail (TM), to treat fungal infection of the nail and Opterone(R), to treat male hypogonadism. In addition to EcoNail and Opterone, our pipeline of early-stage product candidates is based on our SEPA, MacroDerm and DermaPass drug delivery technologies. For more information visit our website, http://www.macrochem.com.
About Equities Magazine
Equities Magazine is focused on bringing together corporate executives and corporate and institutional investment professionals who closely follow and invest in mid cap and small cap growth companies. Equities corporate conferences now celebrate 25 years of bridging the gap between emerging public companies and the investment community.
Forward-Looking Statements
With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled "Risk Factors" in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.com.
Contact: MacroChem Corp.: Bernard Patriacca - VP/CFO (781)-489-7310 Investor Relations: The Investor Relations Group, Inc. Jordan Silverstein/Christine Berni (212) 825-3210
MacroChem CorporationCONTACT: Bernard Patriacca - VP/CFO, of MacroChem Corp., +1-781-489-7310;or Investor Relations, Jordan Silverstein or Christine Berni, of TheInvestor Relations Group, Inc., +1-212-825-3210
